Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009143 | 0.89 | CRBN (0.49) | CRBNDDB1USP30EPHX2GPR119 | |
| SCHEMBL23123218 | 0.89 | CRBN (0.49) | CRBNDDB1USP30EPHX2GPR119 | |
| SCHEMBL23123241 | 0.88 | DDB1 (0.40) | CRBNDDB1ALDH1A1TSHR | |
| SCHEMBL27148853 | 0.88 | CRBN (0.46) | CRBNDDB1USP30EPHX2GPR119 | |
| SCHEMBL23134799 | 0.86 | CRBN (0.36) | CRBNDDB1GPR119 | |
| SCHEMBL29720863 | 0.86 | CRBN (0.36) | CRBNDDB1GPR119 | |
| SCHEMBL23134748 | 0.85 | PDE4B (0.40) | CRBNDDB1GPR119 | |
| SCHEMBL23133980 | 0.84 | DDB1 (0.38) | CRBNDDB1ALDH1A1TSHR | |
| SCHEMBL23173797 | 0.83 | CRBN (0.56) | CRBNDDB1USP30EPHX2GPR119 | |
| SCHEMBL23121717 | 0.82 | DDB1 (0.40) | CRBNDDB1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4041724-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| CN-114641473-A | BRD9 bifunctional degradation agent and use method thereof | 诺华股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | BRD9, BRD2, BRD1 | CRBN 850/4885DDB1 1555/4885USP30 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.